- No direct evidence: No clinical trials have tested valerian specifically for appetite control or weight loss in humans.
- Indirect logic exists but is unproven: Valerian is studied mainly for sleep and anxiety; poor sleep and stress can drive overeating, but the chain from valerian → better sleep → less appetite has not been tested as a whole.
- Skip it for this purpose: Given the absence of appetite-specific evidence, valerian is not a recommended choice if appetite control is your goal.
- Safety caution: Valerian interacts with sedatives, alcohol, and certain medications, and should be avoided in pregnancy and in children under 3.
What the evidence shows
Valerian (Valeriana officinalis) has been studied most extensively as a sleep aid and anxiolytic. A 2006 meta-analysis found modest evidence that valerian may improve subjective sleep quality without producing side effects (Bent et al., 2006). A smaller body of work suggests it may mildly reduce anxiety (Andreatini et al., 2002). That is essentially where the peer-reviewed story ends.
When it comes to appetite control specifically, the literature is effectively empty. A search of clinical trial registries and published literature turns up no randomized controlled trials, no dose-finding studies, and no observational cohorts examining valerian as an intervention for appetite, caloric intake, hunger hormones (such as ghrelin or leptin), or body weight. Any website suggesting otherwise is extrapolating well beyond what the data support.
The indirect argument sometimes made goes like this: sleep deprivation increases ghrelin (the hunger hormone) and decreases leptin (the satiety hormone), nudging people toward overeating (Spiegel et al., 2004). If valerian improved sleep, it might — in theory — help restore normal hunger signaling. That is a plausible chain of logic, but "plausible" is not "proven." The intermediate step (does valerian reliably improve objective sleep quality?) is itself uncertain; most valerian sleep studies rely on self-report, and effect sizes tend to be small.
Similarly, stress-driven eating is a real phenomenon (Yau & Potenza, 2013), and if valerian reduced anxiety, it might reduce stress eating. Again, this remains speculative for appetite purposes — no trial has closed that loop.
Bottom line on evidence strength: weak to nonexistent for appetite control. The honest answer is that we simply do not know whether valerian influences appetite, and there is no good reason to assume it does.
How it works (mechanism)
Valerian's best-characterized active constituents are valerenic acid and isovaleric acid, along with a family of compounds called iridoids (valepotriates). Valerenic acid appears to modulate GABA-A receptors — the same receptors targeted by benzodiazepines — which is the likely basis for its sedative and anxiolytic effects (Benke et al., 2009). Some constituents may also weakly interact with serotonin receptors, though the clinical significance of this is unclear.
None of these pathways have a known direct connection to appetite regulation. There is no evidence that valerian affects ghrelin, leptin, glucagon-like peptide-1 (GLP-1), or other hormones meaningfully involved in hunger and satiety. The GABAergic mechanism produces calming and sedation — not appetite suppression.
Dose & timing if you try it
Because there is no evidence-based dose for appetite control, the information below reflects doses used in the sleep literature only. Do not interpret this as a recommendation to use valerian for weight loss.
- Typical studied dose: 300–600 mg of standardized root extract, taken 30–60 minutes before bedtime.
- Form: Dried root extract is most commonly studied; teas and tinctures are also used but standardization varies.
- Duration: Some sleep studies ran 4–6 weeks; long-term safety data beyond this window are limited.
- Timing note: Because valerian is sedating, daytime use for appetite management would carry a meaningful drowsiness risk — an additional reason it is poorly suited to this purpose.
If your actual goal is better sleep as part of a broader weight-management strategy, speak with a clinician first. There are behavioral interventions (cognitive behavioral therapy for insomnia, or CBT-I) with far stronger evidence than any supplement.
Who should skip
- Pregnant or breastfeeding individuals: Safety has not been established; some valepotriates have shown cytotoxic activity in laboratory settings. Avoid.
- Children under 3: Insufficient safety data.
- People taking CNS depressants: Valerian may potentiate the effects of benzodiazepines, barbiturates, alcohol, and other sedative drugs, increasing the risk of excessive sedation.
- People on certain medications metabolized by CYP3A4: Early in-vitro data suggest possible enzyme interactions; discuss with a pharmacist if you take statins, antiretrovirals, or immunosuppressants.
- Those with liver conditions: Rare case reports of hepatotoxicity have been associated with multi-herb products containing valerian; causality is unclear but worth flagging.
- Anyone who needs to drive or operate machinery: Sedation risk makes daytime use inadvisable.
Bottom line
Valerian has no meaningful evidence supporting its use for appetite control. The theoretical pathways (better sleep, less stress eating) are interesting but completely untested for this application. Choosing valerian to manage hunger means spending money on something that has not been shown to work for that purpose and accepting a non-trivial sedation risk in the process.
If you are looking for appetite management approaches with actual clinical support, the conversation should center on dietary fiber intake (Slavin, 2005), protein distribution across meals, structured eating patterns, and — for clinically significant obesity — evidence-based medical therapies. For sleep specifically, CBT-I remains the first-line recommendation before any supplement.
Save valerian for what it has the most (still modest) evidence for: falling asleep. For appetite, skip it.
References
- Andreatini, R., Sartori, V. A., Seabra, M. L., & Leite, J. R. (2002). Effect of valepotriates (valerian extract) in generalized anxiety disorder. Phytotherapy Research, 16(7), 650–654.
- Benke, D., Barberis, A., Kopp, S., Altmann, K. H., Schubiger, M., Vogt, K. E., … Möhler, H. (2009). GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology, 56(1), 174–181.
- Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for sleep: A systematic review and meta-analysis. The American Journal of Medicine, 119(12), 1005–1012.
- Slavin, J. L. (2005). Dietary fiber and body weight. Nutrition, 21(3), 411–418.
- Spiegel, K., Tasali, E., Penev, P., & Van Cauter, E. (2004). Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine, 141(11), 846–850.
- Yau, Y. H., & Potenza, M. N. (2013). Stress and eating behaviors. Minerva Endocrinologica, 38(3), 255–267.
Note: No high-quality clinical trials exist examining valerian specifically for appetite control or weight loss. The references above support individual mechanistic claims only.
```